Transarterial chemoembolization (TACE)-induced complete pathological response (CPR) is known to improve postresection outcomes of hepatocellular carcinoma (HCC). We aimed to assess the prognostic effects of CPR after preoperative TACE for HCC in patients who underwent hepatic resection (HR) or liver transplantation (LT). The clinical outcomes of patients showing CPR after HR (n 5 110) or LT (n 5 233) were analyzed. The control groups comprised patients with minimal recurrence risk as na€ ıve single HCC £ 2 cm for HR (n 5 476), and 1 or 2 HCCs £ 2 cm for LT (n 5 184). Among HR study patients, 1-, 3-, and 5-year tumor recurrence rates were 18.5%, 50.6%, and 58.7% respectively, which were higher than those of controls (P < 0.001). The 1-, 3-, and 5-year patient survival rates were 97.8%, 82.0%, and 69.1%, respectively, which were lower than those of controls (P < 0.001). Among LT study patients, 1-, 3-, and 5-year tumor recurrence rates were 4.1%, 7.9%, and 7.9%, respectively, which were higher than those of controls (P 5 0.019). The 1-, 3-, and 5-year patient survival rates were 92.7%, 89.2%, and 86.9%, respectively, which were not different than those of controls (P 5 0.11). LT recipients had lower recurrence and higher survival rates compared with HR patients (P < 0.001). The tumor recurrence site was mainly intrahepatic in HR patients. There was no difference between the incidences of extrahepatic recurrence in the HR study group and all-site recurrence in the LT study group (P 5 0.61). We concluded that the prognostic effect of TACE-induced CPR for HCC patients appears to be limited to downstaging. LT recipients benefited more from CPR than HR patients.
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and is one of the leading causes of cancer-related deaths.
(1) Hepatic resection (HR) is currently accepted as the preferred treatment for HCC. (2, 3) HR is also considered a challenging surgical procedure in the presence of advanced liver cirrhosis, thus liver transplantation (LT) has been accepted as a definitive treatment for both liver cirrhosis and HCC.
For HCC, various antitumor treatments are often performed with a therapeutic intention of cure or downstaging, especially in patients with liver cirrhosis, multiple tumors, or macrovascular invasion. Transarterial chemoembolization (TACE) has often been performed as an initial HCC treatment. We did not perform preoperative TACE routinely to improve postresection outcome because its prognostic benefit with respect to complete or partial tumor necrosis remains unclear. Contradictory results exist regarding the prognostic value of the pathological response to TACE, which is likely due to widely varying extents of observed tumor necrosis. (4) (5) (6) (7) (8) If HCC recurrence happens or viable HCC portion remains after TACE with or without other locoregional treatments, a small number of patients may be indicated for HR or LT as a salvage treatment.
In contrast, a complete pathological response (CPR) indicates the absence of viable tumor cells and is thus regarded as a reliable predictor of favorable outcomes after HR or LT. (9, 10) This study aimed to investigate the prognostic effect of CPR in patients who underwent HR or LT and to quantify the risk of tumor recurrence through comparison with the corresponding control groups that had minimal risk of tumor recurrence.
Patients and Methods

STUDY DESIGN AND PATIENT SELECTION
The HCC database at our institution was searched to identify patients who underwent primary HR or LT for HCC over a 15-year period from January 2000 to December 2014; 6049 HR patients and 1334 LT recipients were initially identified.
For HR and LT study groups, the exclusion criteria were the absence of preoperative TACE, repeat HR or salvage LT after initial HR, and combined HCCcholangiocarcinoma. CPR was defined as the absence of viable tumor cells in any nodule (tumor necrosis 99%). After reviewing pathological reports, we identified 343 patients showing CPR in the surgical liver specimens. HR and LT study groups had 110 and 233 patients representing 1.8% and 17.5% of their parent populations, respectively (Fig. 1) .
Because CPR was regarded as a prognostic factor indicating favorable outcomes, we decided to assess whether the postoperative risk of tumor recurrence after CPR can be minimized or not. Each HR and LT control group was selected to have minimal risk of tumor recurrence. The inclusion criteria for the HR control group were solitary HCC 2 cm, absence of neoadjuvant treatment, and R0 resection, thus they are consistent with early stage (A) of the original Barcelona Clinic Liver Cancer staging classification. (11) During the study period, 476 patients who met the above conditions were included in the HR control group.
The super-selection criteria for LT were partially applied to patient selection for the LT control group (12) : the inclusion criteria were 1 or 2 tumors, HCC 2 cm, and the absence of neoadjuvant treatment, but no limit for alpha-fetoprotein (AFP) levels. During the study period, 184 patients who met the above conditions were included in the LT control group.
The patient numbers in these 2 control groups were estimated to be large enough to show a statistical significance at a 10% survival difference with a set type I error (a) of 0.05 and type II error (b) of 0.20 (MedCalc version 15.11.4; MedCalc Software, Ostend, Belgium).
Patient medical records were retrospectively reviewed after approval by the institutional review board of our institution. Patients were followed up until June 2016 through medical record review; thus, the patient follow-up period was 18 months or until patient death. All patients were completely followed up to identify survival status with the assistance of the National Health Insurance Service.
PREOPERATIVE DIAGNOSIS
Korean individuals with chronic liver disease were regularly followed up to detect HCC according to the Korean Association for the Study of the Liver guidelines. (13, 14) Routine preoperative evaluations for HCC included abdominal and chest computed tomography, magnetic resonance imaging, 2-18 F-fluoro-2-deoxy-dglucose positron emission tomography (FDG-PET), and upper gastrointestinal endoscopy. Percutaneous biopsies were performed with ultrasonography guidance when imaging study findings were inconclusive, particularly in cases of differential diagnosis with intrahepatic cholangiocarcinoma. The details of this preoperative evaluation process have been described previously. (2, 15) The upper normal ranges of AFP and protein-induced by vitamin K absence or antagonist II (PIVKA-II; des-c-carboxy prothrombin) in our institution are 7.5 ng/mL and 40 mAU/mL, respectively.
PREOPERATIVE TACE AND PATHOLOGICAL ASSESSMENT
The purposes of preoperative TACE are diverse and include definitive treatment with curative intent, palliative cytoreduction therapy, downstaging treatment, response tests for LT suitability, or combinations thereof, (15) thus a majority of patients underwent multiple sessions of TACE before HR or LT. Because of such complexity regarding the purpose of preoperative TACE, we did not divide the patients according to the purposes in our analysis.
Regardless of performing TACE at our institution or before referral to our institution, TACE was typically performed in accordance with Korean guidelines. The procedures for TACE have been previously reported. (15) We defined CPR as an area of necrosis including 99% of the total tumor volume, thus showing absence of viable tumor cells in any nodule. If there were multiple tumors, we required that no nodule have any viable tumor cells. Because of such absence of viable tumor cells, the diagnosis of HCC was made in the HR and LT study groups through preoperative evaluation using imaging studies and tumor markers. In addition to TACE, a small proportion of patients (2%) had also undergone radiofrequency ablation therapy, but the effect of radiofrequency ablation was not taken into consideration due to its small proportion and to avoid complex analysis.
HR AND LT
Because salvage LT following initial HR was intentionally excluded from this study, the indications for HR and LT were established separately.
The extent of HR was primarily determined based on future remnant liver volume considering tumor-free resection margins and hepatic functional reserves. Assessment of the HR rate and hepatic functional reserve was previously described in detail. (16) Anatomical hepatectomy included resection of 1 or more adjacent hepatic segments along the hepatic vasculature.
For LT, no priority was provided to HCC patients awaiting deceased donor liver transplantation (DDLT) in the Korean setting during the study period. The indications of living donor liver transplantation (LDLT) for HCC patients were previously described. 
POSTOPERATIVE SURVEILLANCE AND TREATMENTS FOR HCC RECURRENCE
Patients underwent follow-up examinations performed every 1-3 months during the first year after HR and every 3 months thereafter. Most hepatitis B virus (HBV)-associated patients became HBV DNAnegative during outpatient clinic follow-up examinations through vigorous antiviral treatment. After LT, patients had follow-up examinations performed every 1 month during the first year and every 2-3 months thereafter. The detailed follow-up protocol has been described previously. (2, 18) The general principles of treatment for recurrent HCC lesions were applied to all patients enrolled in this study.
STATISTICAL ANALYSIS
Continuous variables are reported as means with standard deviation (SD) or medians with ranges, and were compared using Student t test. Categorical variables were compared using chi-square or Fisher's exact test, as appropriate. Survival curves were generated using the Kaplan-Meier method and compared using a logrank test. A P value of < 0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS, version 20 (IBM, Armonk, NY) and Statistica, version 6.0 (StatSoft, Tulsa, OK).
Results
PATIENT SELECTION ACCORDING TO COMPLETE PATHOLOGIC RESPONSE AFTER TACE
Among the 6049 HCC patients who underwent HR during the study period, 977 (16.2%) were identified as having a medical history of TACE before surgery. The number of patients in the HR study group was 110 (1.8%), thus the incidence of CPR after TACE was estimated as 11.0% after 1.4 6 1.2 sessions of TACE. The median interval period from the initial TACE to HR was 13 months (range, 3-65 months).
Among the 1334 HCC patients who underwent LT during the study period, 738 (55.3%) were identified as having a medical history of TACE before surgery. The number of patients in the LT study group was 233 (17.5%), thus the incidence of CPR after TACE was estimated as 31.6% after 2.2 6 2.4 sessions of TACE, which is higher than in the HR study group (P 5 0.001). The median interval period from the initial TACE to LT was 18 months (range, 2-87 months), which is longer than in the HR study group (P 5 0.001). The detailed patient selection processes are depicted in Fig. 1 . No patient showing CPR demonstrated any lesions showing hypermetabolic uptake on positron emission tomography imaging taken just before HR or LT.
PATIENT DEMOGRAPHICS
The number of patients in the HR study, HR control, LT study, and LT control groups were 110, 476, 233, and 184, respectively. The demographics of these 4 groups are summarized in Table 1 . The number of solitary tumors and the size of the largest tumor were 95 (86.4%) and 4.2 6 2.8 cm in the HR study group, respectively; and 164 (70.4%) and 2.5 6 1.3 cm in the LT study group, respectively.
Anatomical HR was performed in 95 (86.4%) patients in the HR study group and 434 patients (91.2%) in the HR control group (P 5 0.13). The extents of HR are summarized in Table 2 .
LDLT was performed in 211 (90.6%) patients in the LT study group and 176 (95.7%) patients in the LT control group (P 5 0.059). The mean LDLT graft-to-recipient weight ratio (GRWR) was 1.04% 6 0.11% in the LT study group and 1.03% 6 0.12% in the LT control group (P 5 0.38).
TUMOR RECURRENCE AND OVERALL PATIENT SURVIVAL OUTCOMES AFTER HR
During the study period, tumor recurrence occurred in 47 HR study group patients (42.7%) and 129 HR control group patients (27.1%; Table 3 ). Solitary intrahepatic recurrence was the main type of tumor recurrence, which occupied 85.1% of recurrences in the HR study group patients and 94.6% of recurrences in the HR control group patients (P 5 0.040). The 1-, 3-, 5-, and 10-year tumor recurrence rates were 18.5%, 50.6%, 58.7%, and 69.0% in the HR study group and 8.1%, 29.6%, 39.6%, and 62.3% in the HR control group, respectively (P < 0.001; Fig. 2) .
Patient death from all causes occurred in 22 (20.0%) patients in the HR study group and 42 patients (8.8%) in the HR control group (Table 4) . HCC recurrenceassociated death occupied 90.9% of deaths in the HR study group patients and 78.6% of deaths in the HR control group patients (P 5 0.30). The 1-, 3-, 5-, and 10-year patient survival rates were 97.8%, 82.0%, 69.1%, and 49.8% in the HR study group and 99.3%, 95.7%, 89.7%, and 61.6% in the HR control group, respectively (P < 0.001; Fig. 3 ). 
TUMOR RECURRENCE AND OVERALL PATIENT SURVIVAL OUTCOMES AFTER LT
During the study period, tumor recurrence occurred in 17 LT study group patients (7.3%) and 5 LT control group patients (2.7%; Table 3 ). Solitary intrahepatic recurrence comprised 23.5% of all recurrences in the LT study group and 60.0% in the LT control group (P 5 0.27). The 1-, 3-, 5-, and 10-year tumor recurrence rates were 4.1%, 7.9%, 7.9%, and 11.6% in the LT study group and 0%, 1.9%, 1.9%, and 4.3% in the LT control group, respectively (P 5 0.019; Fig. 2 NOTE: Data are given as n (%). group patients (12.5%) and 23 LT control group patients (12.5%; Table 4 ). HCC recurrence-associated death occupied 37.9% of deaths in the LT study group patients and 8.7% of deaths in the LT control group patients (P 5 0.023). The 1-, 3-, 5-, and 10-year patient survival rates were 92.7%, 89.2%, 86.9%, and 80.9% in the LT study group and 96.2%, 93.9%, 91.6%, and 87.8% in the LT control group, respectively (P 5 0.11; Fig. 3 ).
PROGNOSTIC FACTOR ANALYSIS
Tumor recurrence and patient survival rates were significantly different between the HR and LT study groups (both P < 0.001; Figs. 2 and 3 ).
Univariate analysis for tumor recurrence in the HR study group revealed no significant risk factor (AFP of 7.5 versus > 7.5 ng/mL, P 5 0.67; PIVKA-II 40 versus > 40 mAU/mL, P 5 0.39; TACE once versus multiple, P 5 0.61; tumor number single versus multiple, P 5 0.71; tumor size of 4.2 versus > 4.2 cm, P 5 0.38).
Univariate analysis for tumor recurrence in the LT study group was not performed because the tumor recurrence rate was too low to perform reliable analysis.
When comparing the incidences of extrahepatic recurrence in the HR study group with the incidences of all-site recurrence in the LT study group, no 
Discussion
CPR following TACE is regarded as a reliable predictor of favorable outcomes for HCC. (9, 10) The results of this study revealed that TACE-induced CPR results in relatively favorable outcomes after both HR and LT, in which longterm outcomes were roughly comparable to those of patients with HCC of minimal risk for HR and LT.
The incidence of CPR after TACE is a matter of concern because it is closely associated with selection of further treatment modalities. In the present study, the proportion of patients showing CPR in the HR study group was 11.0% after TACE, after a mean of 1.4 6 1.2 sessions. However, it was substantially increased to 31.6% in the LT study group after TACE with a mean of 2.2 6 2.4 sessions. Among the 6049 patients undergoing HR for HCC, 977 (16.2%) underwent TACE, but only 110 (1.8%) showed CPR. There are 2 explanations for this low incidence of CPR in HR patients. First, HR is the preferred initial treatment if the HCC lesion is resectable, thus only a small proportion of surgical patients have undergone TACE before surgery. Second, a majority of patients showing complete radiologic response-as assessed by the modified Response Evaluation Criteria in Solid Tumor (mRECIST) (19) -might not undergo HR. Thus, the 11.0% incidence of CPR in this study does not reflect the actual incidence of TACE-induced CPR.
In a study with 67 LT patients with HCCs <5 cm, a complete radiologic response was observed in 44 (65.7%) patients with 71 nodules, and CPR was confirmed in 53 (55.8%) of 95 nodules showing complete radiologic response. (20) In another study, the probability of CPR was estimated as 47.9% when maximal tumor size was <30 mm, preoperative AFP was <100 ng/mL, and patients had only a single tumor. (10) Although a complete radiologic response was achieved after nonsurgical treatments, including TACE and radiofrequency ablation, a considerable number of HCC patients needed to undergo LT primarily due to concurrent advanced liver cirrhosis. These background differences are reflected in the higher number of TACE sessions and higher incidence of CPR in the LT study group than in the HR study group.
After HR, we found that the tumor recurrence rate was as high as 58.7% after 5 years, although CPR was achieved in all tumors. This 5-year tumor recurrence rate is higher than the 39.6% observed in the HR control group with minimal risk of recurrence. Intrahepatic recurrence was the main type of initial tumor recurrence in both HR study and control groups, and a majority of patient deaths were associated with tumor recurrence. When we analyzed the annual recurrence rates in the HR control group, these rates are not widely variable year by year, which indicates a high probability of de novo HCC development during the follow-up period. In contrast, a majority of tumor recurrences occurred during the first 2 years in the HR study group, implicating a high probability of early intrahepatic metastasis from the primary tumors showing CPR. Thus, CPR itself can be a surrogate pathologic predictor of improved postresection outcomes, but it does not sufficiently reduce the risk of tumor recurrence because recurrent or de novo tumors often develop in the remnant liver. Because TACE-induced CPR decreases or removes only the active tumor load in patients undergoing HR, CPR should not be interpreted as a reliable parameter permitting relaxed follow-up for HCC recurrence surveillance.
To date, 4 randomized controlled trials have assessed the prognostic effects of preoperative TACE for HR (4) (5) (6) (7) ; all the studies showed that pretreatment with TACE did not improve postresection patient survival. We previously reported that preoperative TACE might adversely affect patient survival after HR because a majority of patients showed incomplete pathologic responses. (15) Even in patients showing tumor necrosis 95%, the rates of overall patient survival and tumor recurrence were similar to those of patients without preoperative TACE. Therefore, we suggested that preoperative TACE should be avoided in patients with resectable HCC. (15) The response to TACE is widely variable in HCC patients, thus TACE has been repeatedly performed to enhance treatment response as well as to treat recurrent or new lesions. In a study using the explant livers, it was reported that near-complete tumor necrosis was associated with extensive accumulation of ethiodized oil within a tumor during TACE administration. On post-TACE computed tomography, lack of residual contrast enhancement, decrease in the tumor size, high tumor density due to accumulation of ethiodized oil, and diffuse distribution of ethiodized oil throughout the tumor were correlated with near-complete tumor necrosis upon pathological analysis. (21) In a Korean study with treatment-na€ ıve patients with wellpreserved liver function undergoing TACE for HCC, the overall patient survival was closely associated with both the initial and the best response to TACE. Achievement of complete treatment response at an early time point was the most robust predictor for favorable outcomes. (22) In contrast, there is another study suggesting that best radiological response to TACE does not imply better outcomes. (23) Thus only complete radiological response with normalization of tumor markers after initial or repeated TACE can be a potential reason to delay LT in patients with small HCCs and compensated liver cirrhosis.
The risk of intrahepatic metastasis is nullified after LT because the diseased remnant liver itself is completely resected and all posttransplant tumor recurrences regardless of site including the liver graft itself are regarded as distant metastases, (18) thus they are considered to be the counterpart to extrahepatic tumor recurrence after HR. Our results revealed that the incidence of extrahepatic recurrence in the HR study group was quite similar to the incidence of all-site recurrence in the LT study group, which was expected but had not yet been reported before.
In the field of LT, avoiding HCC recurrence is very important because no effective measure yet exists to prevent or control tumor recurrence. In practice, TACE has been used for downstaging, to test the treatment response for intentional selection of LT candidates, or with curative intent. Several studies have indicated that the prognostic benefit of pretransplant TACE is limited because it works as only a downstaging treatment. (24) (25) (26) (27) However, if CPR of all tumor nodules is achieved, TACE becomes the final phase of downstaging therapy by which the active tumor load might be theoretically minimized. It is generally accepted that CPR itself indicates a dramatic reduction in tumor cell load, which may contribute to the reduction of posttransplant tumor recurrence. (9, 10) We also evaluated posttransplant outcomes of the LT study group under the assumption that they had not undergone TACE. Even without downstaging effects after multiple sessions of TACE, a majority of LT study group patients may have met the Milan criteria and a considerable proportion may have satisfied the super-selection criteria. (12) We previously presented very low recurrence rates in LT recipients satisfying the super-selection criteria or in whom HCC was incidentally detected. (12) Thus, when simply compared with the HR study and control groups, the tumor recurrence rate in the LT study group appears to be substantially improved. However, the prognostic benefit should be assessed objectively because LTassociated prognostic effects and early tumor stages of the native tumors can explain a considerable portion of such benefits. (18) These results implicate that the pure prognostic effect of CPR in the LT study group may be limited similarly to that of the HR study group. However, we believe that there is a definite prognostic advantage of CPR for LT recipients because CPR may further decrease the risk of tumor recurrence in combination with LT-derived prognostic effects and absence of the native diseased liver. Thus, in practice, we regard CPR in LT recipients as a reliable parameter permitting relaxed follow-up for HCC recurrence surveillance. (18) In the present study, we selected only the control group patients with minimal risk of tumor recurrence. If control patients had been selected through a propensity score-matching, it would be possible to quantify the actual prognostic impact from CPR. However, it was practically not possible in the setting of this retrospective study because the tumor profiles before TACE in the study groups were too diverse to select the control patients reasonably and important pathological features such as microvascular invasion were unavailable from the surgical specimens showing CPR. In practice, microvascular invasion was a universal risk factor of tumor recurrence and patient survival. Microvascular invasion was identified in 46 of 476 (9.7%) HR control patients and 16 of 184 (8.7%) LT control patients. In HR control patients, higher recurrence rate was observed in patients with microvascular invasion compared with patients without microvascular invasion. In contrast, there was no difference in recurrence rate in LT control patients according to microvascular invasion.
There are some limitations to this study. This is a retrospective, single-center study in an HBV-endemic area. It will certainly be necessary to validate the prognostic effect of CPR in other geographic regions to extend our results to patients with HCC of various etiologies. Another major limitation is that we intentionally selected only patients with tumor necrosis 99% and thus did not evaluate patients with near-CPR such as > 95% necrosis. A unique strong point of this study is that the survival status of all patients was completely followed up.
In conclusion, we assert that TACE-induced CPR for HCC can be a surrogate pathologic predictor for improved postresection outcomes, but its prognostic effect is confined to downstaging rather than risk minimization. The prognostic benefit of CPR was not substantial after HR, thus strict postoperative surveillance is necessary. In contrast, LT recipients appear to have benefitted more from CPR, permitting less strict follow-up.
